mitoxantrone has been researched along with Cardiovascular Stroke in 3 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Staib, P | 1 |
| Forsch, S | 1 |
| Niedeggen, A | 1 |
| Janssens, U | 1 |
| Cohen, Y | 1 |
| Amir, G | 1 |
| Da'as, N | 1 |
| Gillis, S | 1 |
| Rund, D | 1 |
| Polliack, A | 1 |
| Zivin, JG | 1 |
3 other studies available for mitoxantrone and Cardiovascular Stroke
| Article | Year |
|---|---|
[Percutaneous coronary intervention in a patient with acute myeloid leukemia].
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; | 2012 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; A | 2002 |
Cost-effectiveness analysis with risk aversion.
Topics: Analysis of Variance; Anti-Inflammatory Agents; Antineoplastic Agents; Bias; Cost-Benefit Analysis; | 2001 |